The objective of this investigation was to evaluate phenobarbital transdermal 26 delivery for possible use in paediatric care. In vitro experiments were performed 27 using intact pig skin and barriers from which the stratum corneum had been stripped 28 to different extents to model the less resistant skin of premature babies. Cathodal 29 iontophoretic delivery of phenobarbital was superior to anodal transport and 30 optimised delivery conditions were achieved by reduction of competing co-ion 31 presence in the drug formulation. Phenobarbital transport across intact or partially 32 compromised skin was controlled by iontophoresis which was more efficient than 33 passive diffusion. Across highly compromised skin, however, passive diffusion 34 increased drastically and iontophoretic control was lost. Overall, this study 35 demonstrates the feasibility of phenobarbital transdermal delivery for paediatric 36 patients. 37 38
Introduction 42
Phenobarbital is a barbiturate drug used in the treatment of different forms of 43 paediatric epilepsy and status epilepticus (BNF for children, 2011) being the first-line 44 choice to control neonatal seizures (Lehr, 2005 , Blume, 2009 , Ouvrier, 1982 . It is 45 also used to treat neonatal abstinence syndrome both in the case of sedative-46 hypnotic withdrawal and as an adjunct therapy to treat opiate withdrawal symptoms 47 intravenous injections are also frequently used, but care must be taken to dilute the 79 8 0.4 mA (0.5 mA.cm -2 ) was delivered using Ag/AgCl electrodes and a power supply 161 (KEPCO 1000M, Flushing, NY, USA). Hourly samples (0.5 mL) of the receptor phase 162
were withdrawn for analysis and replaced with fresh receptor solution. Experiments, 163 which compared phenobarbital iontophoretic delivery through different skin 164 barriers, also monitored passive permeation (same donor solution) post-current 165 termination. Separate passive diffusion controls (no current) through both intact and 166 compromised skin were also performed. The details of the experiments performed 167 are in Table 1 . 168
Another series of experiments examined the effect of iontophoresis on the 169 passive permeability of intact skin to phenobarbital. Prior to the permeation study, 170
and in the absence of phenobarbital (i.e., with a donor compartment containing 171 water, pH 8.5, and receptor compartment containing unbuffered 154 mM NaCl), a 172 0.4 mA current was applied for 5 hours. At this point, the current was terminated 173 and the compartments were then emptied and refilled with a donor solution 174 containing phenobarbital and with fresh receptor solution. Passive diffusion was 175 then followed for 24 hours. To account for any effect of skin hydration during the 176 pre-iontophoresis, the same experiment was repeated without application of current 177 and with the donor and receptor compartments being filled with water and 154 mM 178 NaCl, respectively. 179
Phenobarbital and chloride analysis 180
Quantification of phenobarbital was performed by high performance liquid 181 chromatography with UV detection (215 nm). The method was modified from a 182 previous publication (Sekkat, 2004b) and used a Jasco HPLC system (PU-980 pump 183
with an AS-1595 autosampler, a UV-975 UV-VIS detector, and an Acclaim 120, C189 (150 x 4.6 mm, 5µm) reversed-phase column (Dionex, UK) which was thermostated 185 at 30 °C). The mobile phase, pumped at 1 mL.min -1 , consisted of phosphate buffer 186 (0.067 M KH 2 PO 4 ) and acetonitrile (70:30) and the pH was adjusted to 6 with NaOH. pre-iontophoresed, and pre-hydrated skin, respectively. Passive diffusion across pre-219 iontophoresed skin was significantly higher than through untreated (p < 0.01) and 220 pre-hydrated (p < 0.05) skin. Increased permeability of skin previously exposed to 221 direct current has been previously reported (Green, 1992) . 222
Iontophoretic delivery across intact skin 223
The first donor solution tested was 50 mM sodium phenobarbital in water (pH 224 i.e., in the absence of competing co-ions, is estimated to be 0.035 (determined by 279 substitution of X PHEN =1 in the linear regression equation given in Figure 5) . 280
Permeation across compromised skin 281
The objective of this part of study was to examine the permeation of 282 phenobarbital across barriers representative of those found in premature neonates 283 whose stratum corneum may be absent or not fully developed. Three impaired levels 284 of barrier function were evaluated against intact skin for passive as well as 285 iontophoretic delivery of the drug. The average TEWL measurements (g.m -2 .h Previously, a similar phenobarbital permeation rate across intact full-thickness 306 pig ear skin was measured when the drug was delivered from a saturated solution of 307 the unionised drug (4.3 mM) at pH 5 (Sekkat, 2004b) . Permeation across fully 308 compromised skin was ~30 times higher than that through the intact barrier. In 309 contrast, the enhancement factor observed in this work was more than 900-fold due, 310 at least in part, to the fact that most of the drug was ionised (~3.7 mM unionized) 311 and hence in a less favourable form for passive permeation. With progressive 312 removal of the stratum corneum, the ionised and neutral forms of phenobarbital 313 permeated through the less-resistant skin barrier at much higher rates. Similar 314 behaviour has been seen for 5-fluorouracil (Fang, 2004) , with removal of the stratum 315 corneum leading to an increase in passive diffusion from < 0.03 µmol.cm -2 in 6 hours 316 to approximately 17 µmol.cm -2 a difference of more than 550-fold. 317 Figure 6 summarizes the iontophoretic delivery of phenobarbital through 318 compromised skin barriers. The fluxes measured during 5 hours of iontophoresis (0.4 319 mA) application followed by 5 hours of passive diffusion are shown. Table 2 presents 320 the fluxes during the last hour of the permeation studies. The iontophoretic fluxes 321 observed increased with the level of skin impairment but complete removal of the 322 stratum corneum only resulted in a 3.6-fold enhancement relative to intact skin 323 (Table 2) . When the contribution of passive diffusion is taken into account, theskin barriers tested (Table 2 ). In fact, no significant differences were found between 326 these values. It follows that while iontophoretic flux remained constant and 327 independent of the skin barrier function, passive diffusion increased remarkably as 328 the skin was progressively compromised and eventually overshadowed any benefits 329 from iontophoresis. Qualitatively, these results are consistent with those reported 330 for lidocaine hydrochloride (Sekkat, 2004b) , for which the total iontophoretic 331 delivery was practically the same across intact (1.8 ± 0.5 mg.cm -2 ) and tape-stripped 332 skin (1.9±0.3 mg.cm -2 ). In contrast, the passive permeability of lidocaine HCL 333 increased from 7x10 -4 ± 4x10 -4 mg.cm -2 across intact skin to 0.1±0.07 mg.cm -2 334 through a fully tape-stripped barrier. Quantitatively, however, the difference 335 between the behaviour of lidocaine and phenobarbital is important. In the case of 336 lidocaine, the passive diffusion of the drug even across fully-compromised skin is still 337 an order of magnitude smaller than iontophoretic delivery; electrotransport can be 338 used, therefore, to control drug input independent of the status of skin barrier 339 function. For phenobarbital, on the other hand, passive transport increases 340 significantly with progressive derangement of the barrier, ultimately overwhelming 341 iontophoretic delivery, which is no longer able to exercise control over the 342 absorption of the drug when the stratum corneum has been compromised. 343
Finally, a summary of the passive and iontophoretic transport of phenobarbital 344 as a function of TEWL (reflecting barriers of varying competence) is shown in Figure  345 7. The slopes of the linear regressions through the passive and iontophoretic fluxes 346 are not significantly different. This emphasizes the point made above that, once the 347 function of the stratum corneum has been undermined (>50%), the passive transportof phenobarbital exceeds that due to iontophoresis and dominates the transdermal 349 delivery of the drug. 350
Feasibility of phenobarbital transdermal delivery 351
Phenobarbital is used for different purposes in neonatal and paediatric patients. Table 3 calculates the passive and iontophoretic patch sizes required to deliver 366 maintenance doses between 2 and 10 mg.kg -1 .day -1 (0.3 to 1.6 µmol.kg -1 .h -1 ) i.e., 367 amounts spanning the three potential applications of phenobarbital discussed 368 above. The fluxes used in these calculations were those measured when the donor 369 solution was 50 mM of drug in water at pH 8.
370
Assuming a quantitative in vitro-in vivo correlation, transdermal delivery ofprogressively more effective in providing desirable rates of delivery while keeping 375 patch size reasonable (Table 3) . For safety reasons, and the variable degree of barrier 376 immaturity in the premature neonate, transdermal patches with rate-limiting 377 membranes may be preferable, to ensure rate-control and to avoid potential 378 toxicity. A key challenge with premature neonates is to compensate the rate of drug 379 delivery for the degree of barrier maturation. 380
Premature neonates of only 23-25 weeks gestational age may require more 381 than 4 weeks to develop a full functional stratum corneum (Kalia, 1998); whereas 382 those born at 32 weeks of more have a barrier function that is close to fully 383 functional. To treat this "moving target" would require passive patches in a variety of 384 sizes (and even designs, e.g., rate-controlling versus matrix); alternatively 385 iontophoresis might prove more useful in that the intensity and duration of current 386 can be "tuned" to provide the required drug input. This flexibility in dosage form 387 design and operation would rely, of course, on the application of TEWL 388 measurements to pinpoint barrier function status in the patient (Fluhr, 2006 , Levin, 389 2005 . 390 Table 3 also shows that iontophoresis may deliver therapeutic amounts of 391 phenobarbital to infants of 1 month or more to young children. For older children, 392 however, phenobarbital transdermal delivery may not be useful because the 393 requisite patch area becomes too large. For example, the patch sizes required to 394 deliver 2-10 mg.kg -1 .day -1 would be 4-20 cmand other formulation variables (such as pH) on the skin of infants and premature 399 neonates. 400
Conclusions 401
This study demonstrated that cathodal iontophoresis of phenobarbital through 402 intact skin is more efficient than anodal iontophoresis and passive diffusion. 
